title: Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
abstract: Since its initial description approximately 50 years ago, there has been an impressive evolution in therapies for hairy cell leukemia. Long-term follow-up with 2-cholorodeoxyadenosine and 2'-deoxycoformycin demonstrates that both agents result in a high complete remission rate and overall survival. Relapse rates appear to be between 20% and 30%. Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A immunoconjugate, BL-22.
authors.affiliation: Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair Street, Suite 850, Chicago, IL 60611, USA. m-tallman@northwestern.edu
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Anaadriana
authors.initials: A
authors.lastname: Zakarija
mesh_terms: D036002:ADP Ribose Transferases / Q000737:chemistry; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000096:biosynthesis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000737:chemistry; D015815:Cell Adhesion Molecules / Q000096:biosynthesis; D017338:Cladribine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005098:Exotoxins / Q000737:chemistry; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D037102:Lectins / Q000096:biosynthesis; D007943:Leukemia, Hairy Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D015649:Pentostatin / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D051918:Sialic Acid Binding Ig-like Lectin 2; D013997:Time Factors; D016896:Treatment Outcome; D037521:Virulence Factors / Q000737:chemistry; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D015815:Cell Adhesion Molecules; D017338:Cladribine; D005098:Exotoxins; D007166:Immunosuppressive Agents; D037102:Lectins; D015649:Pentostatin; D000069283:Rituximab; D051918:Sialic Acid Binding Ig-like Lectin 2; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C497867:CD22 protein, human